Tyco buys US Surgical for $3.3 billion
This article was originally published in Clinica
Executive Summary
US Surgical brought in fresh reserves last week in its long-running battle with the industry leader, Johnson & Johnson, for a share of the medical disposables market. In the second largest deal in medical device history, the company agreed to be acquired by the industrial group, Tyco International, for $3.3 billion in stock.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.